Fate Therapeutics FATE 深 沪
等待开盘 09-17 09:30:00 美东时间
0.9507
-0.005
-0.53%
华盛通- 最 高0.9999
- 今 开0.96
- 成交量 84.17万股
- 最 低 0.9431
- 昨 收 0.9558
- 总市值 1.09亿
- 52周最高 3.795
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6611
- 委 比 99.63%
- 总股本 1.15亿
- 历史最高 121.16
- 量 比 0.58
- 振 幅 5.94%
- 历史最低 0.6611
- 每 手 1
- 风险率 1.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多硬核实力再获认可！广电运通在算法与数据应用领域取得多项突破
核心导读 近日，广电运通各成员企业在前沿技术创新、国内数据应用领域与市场拓展持续取得重大突破，始终坚持用硬核实力诠释行业自信，以实际行动彰显企业使命。像素数据...
09-01 18:04
Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies, announced its participation in two upcoming investor conferences: the 2025 Wells Fargo Healthcare Conference on September 3, 2025, in Boston, MA, and the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York, NY. The Company will host one-on-one meetings and a fireside chat during these events. Live and archived web...
08-25 12:00
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure...
08-15 00:22
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $2.5
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $4 to $2.5.
08-13 20:52
Fate Therapeutics Announces Corporate Restructuring Plan
An update from Fate Therapeutics ( ($FATE) ) is now available. On August 7, 202...
08-13 04:44
Fate Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate, Sales $1.907M Beat $1.011M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 12.12 percent increase over losses of $(0.33) per share from
08-13 04:17
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported progress in its FT819 CAR T-cell therapy for autoimmune diseases, including positive interim data in lupus nephritis and extrarenal lupus, and expanded its Phase 1 trial to include additional B cell-mediated autoimmune diseases. The company also amended its collaboration with Ono Pharmaceuticals for a second solid tumor CAR T-cell candidate. Additionally, the FDA allowed the IND application for FT836, an MICA/B-targeted...
08-12 20:01
HOKA ONE ONE于北京三里屯开HOKA MAFATE HOUSE全国首店
HOKA ONE ONE®于北京三里屯太古里首次揭幕HOKA MAFATE HOUSE限时体验空间。此次携山野基因入侵都市潮流。同时发布新款MAFATE SP...
08-11 15:01
OSR appoints Andreas Niethammer as Chief Medical Officer of Vaximm AG
OSR Holdings (NASDAQ:OSRH) announced on Tuesday the appointment of Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR company developing a platform of orally administered target-specific...
07-15 19:58
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics granted 30,000 stock options with a $1.12 exercise price and 37,900 RSUs to new employees on July 2, 2025, under its equity plan. These grants were approved by the Compensation Committee as inducements for employment. Options and RSUs vest over four years, with 25% vesting annually and the remainder in monthly installments, contingent on continuous employment.
07-03 17:05
